GT Biopharma, Inc. (GTBP) will restate its interim quarterly financial statements for the periods ended June 30, 2025, and September 30, 2025. The restatement is due to an error in classifying 'Greenshoe Rights' (stock purchase rights for Series L Preferred Stock) as equity instead of a liability under ASC 480. The Greenshoe Rights met liability classification criteria due to redemption provisions that could require cash settlement upon events outside the company's control. For the three months ended June 30, 2025, Net Loss increased from $(1,433,000) to $(30,169,000), and Net Loss Per Share increased from $(0.55) to $(10.92). For the six months ended June 30, 2025, Net Loss increased from $(2,209,000) to $(30,945,000), and Net Loss Per Share increased from $(0.90) to $(12.12). For the nine months ended September 30, 2025, Net Loss increased from $(5,323,000) to $(22,646,000), and Net Loss Per Share increased from $(1.84) to $(8.90). The Greenshoe Rights liability was extinguished and reclassified to equity in September 2025, resolving the classification issue going forward. The adjustments did not impact total net cash provided by operating, investing, or financing activities for any applicable periods.